Clinical Trial: Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07688928) titled 'Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism' on June 30.

Brief Summary: The goal of this study is to compare the efficacy and safety of finerenone versus spironolactone in the treatment of hypertension due to primary aldosteronism.

It will be a randomized, double-blind, active-controlled, parallel-group clinical trial conducted at the Endocrine Hypertension Clinic, Department of Endocrinology, BSMMU. A total of 104 adult patients with confirmed primary aldosteronism will be enrolled and randomized equally to receive either finerenone (10-40 mg/day) or spironolactone (25-100mg/da...